From California to Cambridge: finance ace strengthens Nuclera board
Since August 2023, he has been CFO at Telesis Bio, a Californian company specialising in automated synthesis technology for therapeutic discovery. He brings extensive financial experience from large life science tool manufacturers to Nuclera’s leadership team as the company continues its global commercial expansion strategy following a $75 million series C close.
Nuclera is accelerating protein expression and optimisation through its benchtop eProtein Discovery™ system.
During his time at Telesis Bio, Kullback oversaw the restructuring of operational expenses resulting in a ~70 per cent decrease. He brings over 30 years of experience as a CFO, focusing on financial and manufacturing operations, mergers and acquisitions as well as public markets across multiple publicly traded companies.
He previously served as CFO at BioLegend Inc., a worldwide provider of antibodies and life science reagents, where he helped manage the company’s $5.25 billion sale to NYSE listed Revvity (previously PerkinElmer), the largest acquisition in Revvity’s history.
He also negotiated and closed acquisitions and investments whilst CFO at NASDAQ listed medical device company, Lombard Medical, prior to its acquisition by Shanghai-based MicroPort Scientific Corporation.
He has also held senior financial positions at a range of medical device and life science tools businesses during his career.
Dr Michael Chen, CEO and co-founder at Nuclera, said: “Bill’s distinguished career and financial expertise will be instrumental as we push forward with our growth strategy in line with our commercial goals.
“His experience will be invaluable to Nuclera as we scale to address current challenges in protein production by bringing eProtein Discovery to even more researchers.”
Kullback added: “Nuclera’s eProtein Discovery has the potential to transform drug discovery workflows. The company is at an exciting stage as it expands globally and I am looking forward to working with the team to support its growth and drive success at this pivotal stage in Nuclera’s development.”